La Fondation des Gouverneurs de l’Espoir
La Fondation des Gouverneurs de l’Espoir is a major partner of Hôpital Sainte-Justine Foundation. Established in 2002, the foundation’s mission is to make a difference in the lives of children afflicted with cancer.
In 2010, Francine Laplante, President of the Foundation, promised the integration of 6 palliative care rooms at Hôpital Sainte-Justine. A year later, 3 rooms have been completed at a cost of $300,000.
These rooms, all equipped with high technology equipments, help give the children the best care possible and provide them and their families with a comfortable and well decorated environment. They provide the families with a secure, serene and intimate environment, allowing them to give their children tenderness and comfort to accompany them during their last days. The concept has been a great success and the 3 rooms have been greatly appreciated by the children, their families as well as the medical personnel.
It is with great pride that Le Groupe Multi Luminaire and its members have taken on a great challenge by financing the fifth and sixth palliative care room at Hôpital Sainte-Justine at an approximative cost of $200,000. The construction of these rooms was completed in summer 2012.
The Francis Boulva Memorial Fund
Every day, 27 Canadians are diagnosed with a brain tumour. The most common type of primary malignant brain tumour is called a glioblastoma multiforme. The average survival period, even with an aggressive treatment, is less than one year.
During the summer of 2010, Dr. Francis Boulva, a 27 year old McGill resident in paediatrics, passed away only 26 days after being diagnosed. With the hope of quickly finding a cure to this violent disease, his parents created The Francis Boulva Memorial Fund. Since then, the Fund helps support TARGiT, an innovative research program led by Dr. Kevin Petrecca, a well-known neurosurgeon at the Montreal Neurological Institute and Hospital – The Neuro. This program aims at identifying novel molecules that can be targeted to prevent brain cancer invasion.
By using a new therapeutic technology, the TARGiT team has proven that cells that were treated “in vitro” showed much less invasion into the brain as compared with control cells. Encouraged by these results, the TARGiT scientists are now working on developing a preclinical animal model that will mimic the clinical situation, and which they hope will set the stage for clinical testing in humans.
In as quickly as two years, proper financial support permitting, Dr. Petrecca and the TARGiT team firmly believe to be able to use this technique to improve patient outcomes. Thanks to its generous donors, The Francis Boulva Memorial Fund continues to help pursue this promising program.